Preoperative keratometry agreement: vector comparison between the IOLMaster 500, Galilei G2, and a Takagi autorefractor

Autor: Sunny S. Li, James McKelvie, Stuti L. Misra, Henry B. Wallace

Publikováno v: Malaysian Journal of Ophthalmology. 1:244-258

Introduction: Preoperative cataract assessment may involve multiple biometric instruments and it is important that clinicians are aware of the accuracy, limitations, and interchangeability of keratometry measurements conducted on these instruments. P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd2595159ac63a664bd39b3960bb6891
https://doi.org/10.35119/myjo.v1i4.72

Patient-reported quality of life for cataract surgery: prospective validation of the 'Impact on Life' and Catquest-9SF questionnaires in New Zealand

Autor: Sunny S, Li, Stuti, Misra, Henry, Wallace, Lyn, Hunt, James, McKelvie

Publikováno v: The New Zealand medical journal. 132(1503)

The 'Impact on Life' (IoL) questionnaire is used to prioritise publicly funded cataract surgery in New Zealand, however, it has not been formally validated for ophthalmic use. The Catquest-9SF questionnaire is widely used to assess vision-related qua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bb763a97f65768c925e8274f9fb6f652
https://pubmed.ncbi.nlm.nih.gov/31581180

Predicting pseudophakic refractive error: Interplay of biometry prediction error, anterior chamber depth, and changes in corneal curvature

Autor: Henry B. Wallace, Sunny S. Li, Stuti L. Misra, James McKelvie

Publikováno v: Journal of cataract and refractive surgery. 44(9)

To quantify pseudophakic refractive error prediction with the Hill-RBF, Barrett Universal II, and SRK/T formulas and to evaluate the temporal effects of anterior chamber depth (ACD) and keratometric changes on postoperative refraction.Department of O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6210fb1c38315435d859e63a00fb6b72
https://pubmed.ncbi.nlm.nih.gov/30078536

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.

Autor: Badolato R; Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili, Brescia, Italy., Alsina L; Pediatric Allergy and Clinical Immunology Department, Clinical Immunology and Primary Immunodeficiencies Unit, Hospital Sant Joan de Déu, Barcelona, Spain.; Department of Surgery and Surgical Specializations, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain., Azar A; Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD., Bertrand Y; Pediatric Hematology and Oncology Institute, Hospices Civils de Lyon and Claude Bernard University, Lyon, France., Bolyard AA; University of Washington Medical Center, Seattle, WA., Dale D; University of Washington Medical Center, Seattle, WA., Deyà-Martínez À; Pediatric Allergy and Clinical Immunology Department, Clinical Immunology and Primary Immunodeficiencies Unit, Hospital Sant Joan de Déu, Barcelona, Spain.; Department of Surgery and Surgical Specializations, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.; Institut de Recerca Sant Joan de Déu, Barcelona, Spain., Dickerson KE; The University of Texas Southwestern Medical Center, Dallas, TX., Ezra N; California Dermatology Institute, Thousand Oaks, CA., Hasle H; Department of Paediatrics, Aarhus University Hospital, Aarhus, Denmark., Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, South Korea., Kiani-Alikhan S; Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom., Kuijpers TW; Department of Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Kulagin A; RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia., Langguth D; Immunology Department, Sullivan Nicolaides Pathology Auchenflower, Wesley Medical Center, Auchenflower, QLD, Australia., Levin C; Pediatric Hematology Unit, Emek Medical Center, Afula, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel., Neth O; Paediatric Infectious Disease, Rheumatology and Immunology Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, IBiS/Universidad de Sevilla/CSIC, Red de Investigación Translacional en Infectología Pediátrica RITIP, Seville, Spain., Olbrich P; Paediatric Infectious Disease, Rheumatology and Immunology Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, IBiS/Universidad de Sevilla/CSIC, Red de Investigación Translacional en Infectología Pediátrica RITIP, Seville, Spain.; Departmento de Pediatría, Facultad de Medicina, Universidad de Sevilla, Seville, Spain., Peake J; Queensland Children's Hospital, South Brisbane, QLD, Australia., Rodina Y; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia., Rutten CE; Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Shcherbina A; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia., Tarrant TK; Division of Rheumatology and Immunology, Department of Medicine, Duke University, Durham, NC., Vossen MG; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Wysocki CA; The University of Texas Southwestern Medical Center, Dallas, TX., Belschner A; X4 Pharmaceuticals, Boston, MA., Bridger GJ; X4 Pharmaceuticals, Boston, MA., Chen K; X4 Pharmaceuticals, Boston, MA., Dubuc S; X4 Pharmaceuticals, Boston, MA., Hu Y; X4 Pharmaceuticals, Boston, MA., Jiang H; X4 Pharmaceuticals, Boston, MA., Li S; X4 Pharmaceuticals, Boston, MA., MacLeod R; X4 Pharmaceuticals, Boston, MA., Stewart M; X4 Pharmaceuticals, Boston, MA., Taveras AG; X4 Pharmaceuticals, Boston, MA., Yan T; X4 Pharmaceuticals, Boston, MA., Donadieu J; Centre de Référence des Neutropénies Chroniques, Assistance Publique-Hôpitaux de Paris Sorbonne Université-Hôpital d'Enfants Armand-Trousseau, Paris, France.

Publikováno v: Blood [Blood] 2024 Jul 04; Vol. 144 (1), pp. 35-45.

Telephone follow-up one day post-cataract surgery.

Autor: Al-Ani HH; Ophthalmology Department, Auckland District Health Board, Auckland, New Zealand., Li S; Ophthalmology Department, Auckland District Health Board, Auckland, New Zealand., Niederer RL; Ophthalmology Department, Auckland District Health Board, Auckland, New Zealand.

Publikováno v: Clinical & experimental optometry [Clin Exp Optom] 2023 Sep; Vol. 106 (7), pp. 741-745. Date of Electronic Publication: 2022 Dec 04.